Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.59 |
| ▸ | HINT1 | P49773 | 4/20 | 0.55 |
| ▸ | NT5E | P21589 | 1/20 | 0.55 |
| ▸ | GSK3A | P49840 | 2/20 | 0.52 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.52 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.52 |
| ▸ | PNP | P00491 | 2/20 | 0.52 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.52 |
| ▸ | TGM2 | P21980 | 1/20 | 0.51 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.49 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Guanosine SCHEMBL19810339 | 1.00 | HPGD (0.59) | HPGDHINT1NT5EGSK3ARPS6KA3 | |
| Guanosine SCHEMBL19810340 | 1.00 | HPGD (0.59) | HPGDHINT1NT5EGSK3ARPS6KA3 | |
| Guanosine SCHEMBL28166235 | 0.99 | HPGD (0.58) | HPGDHINT1NT5EGSK3ARPS6KA3 | |
| Guanosine SCHEMBL22498410 | 0.97 | HPGD (0.58) | HPGDHINT1NT5EGSK3ARPS6KA3 | |
| Guanosine SCHEMBL11066196 | 0.97 | HPGD (0.58) | HPGDHINT1NT5EGSK3ARPS6KA3 | |
| Guanosine SCHEMBL22498408 | 0.97 | HPGD (0.58) | HPGDHINT1NT5EGSK3ARPS6KA3 | |
| Guanosine SCHEMBL28068227 | 0.97 | NT5E (0.58) | HPGDHINT1NT5EGSK3ARPS6KA3 | |
| Guanosine SCHEMBL22498413 | 0.94 | HPGD (0.54) | HPGDHINT1NT5EGSK3ARPS6KA3 | |
| Guanosine SCHEMBL28048641 | 0.93 | TGM2 (0.57) | HPGDHINT1NT5EGSK3ARPS6KA3 | |
| Guanosine SCHEMBL27555600 | 0.91 | HPGD (0.52) | HPGDHINT1NT5EGSK3ARPS6KA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108103175-A | A kind of method for being used to detect the mutation of EML4-ALK, ROS1 and RET fusion | 序康医疗科技（苏州）有限公司 | 2018-06-01 | — | — | CN | claimed |
| CN-108103055-A | A kind of method of unicellular RNA reverse transcriptions and library construction | 上海亿康医学检验所有限公司 | 2018-06-01 | — | — | CN | claimed |
| CN-107893100-A | A kind of unicellular mRNA reverse transcriptions and the method for amplification | 序康医疗科技（苏州）有限公司 | 2018-04-10 | — | — | CN | claimed |
| CN-106661631-A | Methods for identifying and enumerating nucleic acid sequences, expression, copies or DNA methylation changes using a combination of nucleases, ligases, polymerases and sequencing reactions | 康奈尔大学 | 2017-05-10 | — | — | CN | claimed |
| CN-1578841-A | Annealing control primer and use of the same | VISION GENE CO LTD (KR) | 2005-02-09 | — | — | CN | claimed |
| CN-118043466-A | Substitution of nucleotide bases in self-amplified mRNA | 葛兰素史克生物有限公司 | 2024-05-14 | — | — | CN | disclosed |
| CN-112641951-B | Bioactive supermolecule chiral hydrogel and preparation method and application thereof | 河南工业大学 | 2023-03-28 | — | — | CN | disclosed |
| CN-115074422-A | Detection method of unknown fusion gene | 北京泛生子基因科技有限公司 | 2022-09-20 | — | — | CN | disclosed |
| CN-111549099-B | Third-generation sequencing-based single-cell transcriptome sequencing method | 生物岛实验室 | 2021-07-30 | — | — | CN | disclosed |
| CN-112641951-A | Bioactive supermolecule chiral hydrogel and preparation method and application thereof | 河南工业大学 | 2021-04-13 | — | — | CN | disclosed |
| CN-111549099-A | Third-generation sequencing-based single-cell transcriptome sequencing method | 广州再生医学与健康广东省实验室 | 2020-08-18 | — | — | CN | disclosed |
| CN-110012671-A | Normalization of NGS library concentrations | 斯威夫特生物科学股份有限公司 | 2019-07-12 | — | — | CN | disclosed |
| US-6657052-B1 | Labeling DNA or RNA at a specific site consisting of stable precursor, and only becomes reactive upon activation; alkylating only phosphodiester groups; lactonization reaction traps the trialkylphosphate in a stable form. | UNIVERSITY OF ARKANSAS | 2003-12-02 | — | — | US | disclosed |
| CN-1045539-C | CDNA clones coding for polypepstides exhibiting human granulocyte macrophage and eosinophie cellular growth | SCHERING BIOTECH CORP (US) | 1999-10-13 | — | — | CN | disclosed |
| EP-0532878-B1 | Process for producing acyclic nucleosides | AJINOMOTO KK (JP) | 1999-06-30 | — | — | EP | disclosed |
| US-5792868-A | REACTING RIBONUCLEOSIDE IN THE PRESENCE OF AN ACID CATALYST WITH AN ACID ANHYDRIDE AND AN ESTER, SAPONIFYING | AJINOMOTO CO., INC. (JP) | 1998-08-11 | — | — | US | disclosed |
| US-5688948-A | INTERMEDIATES FOR ACYCLOVIR AND GANCICLOVIR WITH CRYSTALLIZATION | AJINOMOTO CO., INC. (JP) | 1997-11-18 | — | — | US | disclosed |
| US-5336770-A | Transglycosilation process for producing acyclic nucleosides | AJINOMOTO CO., INC. (JP) | 1994-08-09 | — | — | US | disclosed |
| EP-0532878-A2 | Process for producing acyclic nucleosides | Ajinomoto Co., Inc. (JP) | 1993-03-24 | — | — | EP | disclosed |
| CN-1059562-A | Reduce the method for carryover contamination in the amplification procedure | AMGEN INC (US) | 1992-03-18 | — | — | CN | disclosed |